Patients with a history of intracranial hemorrhage have had few safe treatment options for nonvalvular atrial fibrillation. A new study of the Watchman device suggests that may be changing.
Findings from three Cleveland Clinic real-world studies suggest a wider range of patients stand to benefit from the left atrial appendage closure device.
New anticoagulants and a new occlusive device are broadening the options for stroke prevention in patients who are at increased risk for clotting. For now, though, many still use warfarin.